EMA Recommends Caution For Pfizer's Xeljanz
The Agency Has Also Issued Restrictions For Sanofi's Lemtrada
Executive Summary
The European Medicines Agency's drug safety committee has concluded that Pfizer's Xeljanz could increase the risk of blood clots in patients who are already at high risk. The committee has also recommended restrictions on the use of Sanofi's multiple sclerosis drug, Lemtrada.
You may also be interested in...
EU: Pfizer Warns Doctors About Blood Clot Risk With Xeljanz
Now that the European Medicines Agency has finalized its formal safety review procedure into Xeljanz, Pfizer is telling health care professionals what precautions they must take when prescribing the drug.
EU Approvals: Rinvoq Cleared For RA
AbbVie’s upadacitinib has become the latest JAK inhibitor to be approved in the EU for active rheumatoid arthritis, and its selectivity could allow it to compete effectively with established therapies including other JAK inhibitors, TNF-inhibiting biologics and biosimilars.
Roche’s Polivy Among Seven New Drugs On Track For EU-Wide Approval
Seven drugs, including two orphans and two generics, are on track to receive pan-EU approval.